B7-H3: a robust target for immunotherapy in prostate cancer

Trends Cancer. 2024 Jun 4:S2405-8033(24)00093-1. doi: 10.1016/j.trecan.2024.05.003. Online ahead of print.

Abstract

B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.

Keywords: B7-H3; immunotherapy; prostate cancer.